Compare NBIX & IONQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | IONQ |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 1132 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Wholesale Distributors |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.7B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | IONQ |
|---|---|---|
| Price | $149.94 | $47.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 13 |
| Target Price | ★ $180.91 | $66.69 |
| AVG Volume (30 Days) | 1.1M | ★ 28.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $84.91 |
| Revenue Next Year | $13.14 | $53.45 |
| P/E Ratio | $77.03 | ★ N/A |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $115.66 | $25.89 |
| 52 Week High | $160.18 | $84.64 |
| Indicator | NBIX | IONQ |
|---|---|---|
| Relative Strength Index (RSI) | 76.44 | 58.87 |
| Support Level | $133.96 | $44.49 |
| Resistance Level | $158.92 | $47.98 |
| Average True Range (ATR) | 3.63 | 3.59 |
| MACD | 2.00 | 0.40 |
| Stochastic Oscillator | 98.20 | 53.97 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.